DR Reddys Laboratories Ltd. (RDY) financials: revenue, earnings and cash flow
Fiscal 2017–2026 + TTM · from SEC filings · data as of November 13, 2026
Summary
DR Reddys Laboratories’s revenue went from $2.1B in fiscal 2017 to $3.6B in fiscal 2026, growth of about 5.9% a year.
Net income in fiscal 2026 was $455M, a net margin of 12.8%; the best year in this period was 2024 with $668M.
Over the twelve months to September 30, 2026, revenue was $3.5B and net income $297M.
Free cash flow was $195M in fiscal 2026 and positive in 9 of the 10 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5B | $3.6B | $3.8B | $3.4B | $3.0B | $2.8B | $2.6B | $2.3B | $2.2B | $2.2B | $2.1B |
| Gross profit | — | — | $2.2B | $2.0B | $1.7B | $1.5B | $1.4B | $1.2B | $1.2B | $1.2B | — |
| Operating income | — | — | $842M | $813M | $695M | $389M | $332M | $212M | $302M | $183M | — |
| Net income | $297M | $455M | $663M | $668M | $548M | $311M | $236M | $259M | $272M | $151M | — |
| EPS (diluted) | $0.36 | $0.55 | $0.79 | $0.80 | $0.66 | $0.37 | $0.28 | $0.31 | $0.33 | $0.18 | — |
| R&D | — | — | — | — | — | — | — | — | — | — | — |
| Revenue growth | — | −6.3% | +13.8% | +12.0% | +5.9% | +8.9% | +12.0% | +4.1% | +2.0% | +2.1% | −7.2% |
Cash flow
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $328M | $603M | $545M | $545M | $716M | $370M | $488M | $396M | $415M | $277M | — |
| Capital spending | -$278M | -$408M | -$322M | -$197M | -$138M | -$193M | -$133M | -$64M | -$101M | -$143M | — |
| Free cash flow | $50M | $195M | $223M | $348M | $578M | $177M | $355M | $332M | $314M | $134M | — |
| Dividends paid | $71M | $71M | $78M | $80M | $61M | $55M | $57M | $52M | $58M | $61M | $52M |
| Buybacks | — | — | — | — | — | $0 | — | — | $0 | $0 | — |
| Stock-based pay | — | — | $5M | $5M | $5M | $8M | $8M | $7M | $6M | $7M | — |
Balance sheet
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $678M | $678M | $977M | $752M | $585M | $473M | $341M | $358M | $323M | — |
| Debt | — | $537M | $537M | $225M | $106M | $433M | $402M | $235M | $493M | $776M | $86M |
| Equity | — | $3.9B | $3.9B | $3.4B | $2.8B | $2.5B | $2.4B | $2.1B | $2.0B | $1.9B | — |
| Total assets | — | $5.8B | $5.8B | $4.7B | $3.9B | $3.9B | $3.6B | $3.1B | $3.3B | $3.5B | — |
| Shares (diluted) | 833M | 833M | 835M | 835M | 835M | 835M | 835M | 835M | 835M | 835M | 835M |
Margins and returns
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | 58.5% | 58.6% | 56.6% | 53.1% | 54.3% | 53.8% | 54.2% | 53.7% | — |
| Operating margin | — | — | 22.1% | 24.3% | 23.2% | 13.8% | 12.8% | 9.2% | 13.6% | 8.4% | — |
| Net margin | 8.5% | 12.8% | 17.4% | 19.9% | 18.3% | 11.0% | 9.1% | 11.2% | 12.2% | 6.9% | — |
| FCF margin | 1.4% | 5.5% | 5.9% | 10.4% | 19.3% | 6.3% | 13.7% | 14.3% | 14.1% | 6.1% | — |
| ROIC | — | — | 14.1% | 17.5% | 17.8% | 9.7% | 7.8% | 7.3% | 10.0% | 4.6% | — |
| ROE | — | — | 17.0% | 19.9% | 19.5% | 12.4% | 10.0% | 12.6% | 13.4% | 7.8% | — |
Frequently asked questions
What is DR Reddys Laboratories’s annual revenue?
$3.6B in fiscal 2026 and $3.5B over the twelve months to September 30, 2026.
How much profit does DR Reddys Laboratories make?
Net income was $455M in fiscal 2026 (net margin 12.8%).
Is DR Reddys Laboratories’s revenue growing?
No: revenue fell 6.3% in fiscal 2026 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.